Takeda Pharmaceutical Company Limited (TAK) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Takeda Pharmaceutical Company Limited (TAK) Healthcare & Pipeline Overview

Takeda Pharmaceutical Company Limited stands out in the healthcare sector as a global leader in biopharmaceuticals, focusing on innovative treatments for gastroenterology, rare diseases, oncology, and neuroscience, with a robust portfolio of well-established brands.

What Is the Investment Thesis for TAK?

Takeda Pharmaceutical Company Limited presents a strong investment thesis driven by its diversified product portfolio and robust pipeline of innovative therapies. With a market capitalization of $57.6B and a P/E ratio of 49.61, the company demonstrates solid financial health. The ongoing expansion into high-growth therapeutic areas, such as oncology and rare diseases, is expected to drive revenue growth, supported by a gross margin of 58.8%. Additionally, Takeda's strategic collaborations and licensing agreements are likely to enhance its research capabilities and accelerate the development of new treatments. However, potential risks include patent expirations and competition from biosimilars, which could impact future profitability. Overall, Takeda's focus on innovation and patient-centric solutions positions it well for sustained growth in the evolving healthcare landscape.

Based on FMP financials and quantitative analysis

TAK Key Highlights

Market capitalization of $57.6B reflects strong investor confidence.

• P/E ratio of 49.61 indicates a premium valuation compared to industry peers.
• Profit margin of 4.3% highlights operational efficiency in a competitive market.
• Gross margin of 58.8% exceeds industry averages, showcasing strong product profitability.
• Dividend yield of 3.94% provides a steady income stream for investors.

Who Are TAK's Competitors?

TAK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are TAK's Key Strengths?

Established global presence with a strong market share.

• Diverse product portfolio addressing multiple therapeutic areas.
• Strong financial performance with healthy margins.
• Robust pipeline of innovative therapies in development.

What Are TAK's Weaknesses?

High dependency on a few key products for revenue.

• Exposure to patent expiration risks impacting profitability.
• Significant competition in the biopharmaceutical sector.
• Potential challenges in regulatory approvals and compliance.

What Are the Key Risks for TAK?

Financial-distress signal — its Altman Z-Score of 1.17 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Rich valuation — a P/E of 49.61 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
• Exposure to patent expirations that could impact revenue from key products.
• Intense competition from both established and emerging biopharmaceutical companies.
• Regulatory challenges that may delay product approvals or increase compliance costs.
• Fluctuations in currency exchange rates affecting the profitability of international operations.

What Are the Growth Opportunities for TAK?

• Growth opportunity 1: Takeda's expansion into the oncology market is a significant growth driver, with the global oncology therapeutics market projected to reach $450 billion by 2026. The company's innovative products, such as Adcetris and Exkivity, are positioned to capture market share as demand for targeted therapies increases. Takeda's commitment to research and development in this area, backed by strategic partnerships, enhances its competitive advantage.
• Growth opportunity 2: The rare diseases segment presents a substantial opportunity for Takeda, with the global market expected to exceed $300 billion by 2027. Takeda's existing therapies, such as Natpara and Elaprase, along with its robust pipeline targeting rare conditions, position the company to meet the growing demand for specialized treatments, further solidifying its market presence.
• With a strong portfolio of products like Gammagard Liquid and Hyqvia, Takeda is well-equipped to leverage the increasing demand for these life-saving treatments, particularly in immunology and hematology.
• The company's innovative treatments, including Vyvanse and Trintellix, cater to various neurological conditions, positioning Takeda to capitalize on the rising prevalence of neurological disorders and the demand for effective therapies.
• Growth opportunity 5: Takeda's strategic collaborations and licensing agreements with research institutions and biotech firms enhance its innovation capabilities. By leveraging external expertise and resources, Takeda can accelerate the development of new treatments, particularly in high-growth therapeutic areas, driving long-term growth and value creation.

What Opportunities Does TAK Have?

• Expansion into emerging markets with growing healthcare needs.
• Increasing demand for personalized medicine and targeted therapies.
• Strategic acquisitions to enhance product offerings and market reach.
• Growing focus on rare diseases and specialty pharmaceuticals.

What Threats Does TAK Face?

• Intense competition from both established companies and startups.
• Regulatory changes impacting drug approval processes.
• Pricing pressures from healthcare reforms and market dynamics.
• Risk of supply chain disruptions affecting product availability.

What Are TAK's Competitive Advantages?

• Strong brand recognition with established products across multiple therapeutic areas.
• Robust research and development capabilities leading to innovative therapies.
• Extensive global reach with operations in over 70 countries.
• Strategic partnerships and collaborations enhancing innovation and market access.
• Focus on rare diseases and specialty pharmaceuticals, reducing competition.

What Does TAK Do?

Founded in 1781, Takeda Pharmaceutical Company Limited has evolved from a traditional Japanese pharmacy into a global biopharmaceutical powerhouse. Headquartered in Tokyo, Japan, the company operates in over 70 countries and regions, with a strong commitment to research and development. Takeda specializes in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. Its extensive product portfolio includes treatments for gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience, featuring well-known brands such as Entyvio, Gattex/Revestive, and Adcetris. The company has established numerous collaborations and licensing agreements with leading organizations, including Neurocrine Biosciences, the University of Texas MD Anderson Cancer Center, and Arrowhead Pharmaceuticals, enhancing its innovative capabilities. Takeda's strategic focus on patient needs and commitment to advancing healthcare solutions has positioned it as a trusted partner in the global pharmaceutical landscape, addressing unmet medical needs and improving patient outcomes.

What Products and Services Does TAK Offer?

• Research and develop innovative pharmaceutical products.
• Manufacture and market a diverse range of medications.
• Focus on therapeutic areas such as gastroenterology, rare diseases, oncology, and neuroscience.
• Engage in out-licensing agreements to expand product reach.
• Collaborate with leading research institutions and biotech companies.
• Provide treatments under well-known brand names.

How Does TAK Make Money?

• Generate revenue through the sale of patented and generic pharmaceutical products.
• Engage in strategic partnerships and collaborations to enhance research capabilities.
• Leverage a strong pipeline of innovative therapies to drive future growth.
• Utilize out-licensing agreements to monetize research and development efforts.
• Focus on patient-centric solutions to address unmet medical needs.

What Industry Does TAK Operate In?

The global pharmaceutical industry is experiencing significant growth, driven by advancements in biotechnology and an increasing focus on personalized medicine. The market for specialty pharmaceuticals, particularly in oncology and rare diseases, is expected to expand rapidly, with a projected CAGR of over 10% through 2028. Takeda Pharmaceutical Company Limited is well-positioned within this landscape, leveraging its extensive research capabilities and established product portfolio to capitalize on these trends. Competitive pressures from both established players and emerging biotech firms necessitate continuous innovation and strategic partnerships to maintain market share.

Who Are TAK's Key Customers?

• Healthcare providers and hospitals seeking innovative treatments.
• Patients requiring specialized medications for chronic conditions.
• Pharmaceutical distributors and wholesalers for product distribution.
• Research institutions collaborating on drug development.
• Regulatory agencies overseeing pharmaceutical approvals.

Company Profile

Takeda Pharmaceutical Company Limited operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Julie So-Young Kim. TAK has traded publicly since 2010.

Return on equity for Takeda Pharmaceutical Company Limited stands at 2.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.2%, showing how much profit it generates from its asset base. TAK trades at a trailing price-to-earnings ratio of 49.61, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.1%, the inverse of the P/E and a quick read on earnings relative to price.

TAK Valuation & Market Position

With a $57.6B market cap, Takeda Pharmaceutical Company Limited sits in the large-cap segment of the market. Relative to its peer group, TAK's quantitative score of 63/100 is roughly in line with the peer average of 70/100.

Quarterly Financial Performance: Takeda Pharmaceutical Company Limited

Revenue for Takeda Pharmaceutical Company Limited came in at $7.94B during Q1 FY2026, a 9.4% improvement versus the preceding quarter. The company recorded net income of $736.6M, with diluted EPS of $0.23. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, TAK averaged $0.09 in diluted EPS.

Takeda Pharmaceutical Company Limited's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.17 places it in the distress zone, a signal of elevated financial risk.

Takeda Pharmaceutical Company Limited has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 72.1% below estimates on average.

Wall Street analysts project Takeda Pharmaceutical Company Limited revenue of about $4.76T for fiscal 2027, with EPS near $63.06. The estimate reflects 9 contributing analysts.

Over the past six months, Takeda Pharmaceutical Company Limited insiders filed 79 SEC Form 4 transactions — 26 sales and 53 purchases. On net that is roughly 868K shares acquired (about $12.4M) — insiders putting money in tends to read as conviction.

TAK Financials

TAK Latest News

TAK Analyst Consensus

TAK MoonshotScore

Common Questions About TAK (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources